Zeven (dalbavancin) / RaQualia, AbbVie 
Welcome,         Profile    Billing    Logout  
 20 Diseases   6 Trials   6 Trials   1040 News 


«12...45678910111213141516»
  • ||||||||||  dalbavancin / RaQualia, Teflaro (ceftaroline fosamil) / Sumitomo Dainippon, AstraZeneca, Allergan, Zemdri (plazomicin) / Ionis, Achaogen
    Journal:  Important new therapies for methicillin-resistant Staphylococcus aureus. (Pubmed Central) -  Feb 7, 2020   
    All these compounds represent promising options to enhance our antibiotic armamentarium. However, data regarding the use of these new compounds in real-life terms are limited and their best placement in therapy and in terms of optimization of medical resources and balance of cost-effectiveness requires further investigation.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Trial initiation date, Gram positive:  Dalbavancin Outpatient Pilot (clinicaltrials.gov) -  Jan 30, 2020   
    P4,  N=24, Not yet recruiting, 
    Results demonstrated that use of the pH-responsive microspheres could improve A40926 yield from 465 to 602 mg L in a 10-L scale fermenter. Initiation date: Jan 2020 --> May 2020
  • ||||||||||  dalbavancin / RaQualia
    Journal, Combination therapy:  Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus. (Pubmed Central) -  Jan 17, 2020   
    Emergence of reduced susceptibility to vancomycin warrants the development of new antimicrobial agents for the treatment of MRSA...Dalbavancin was tested alone and in combination with five β-lactams: cefazolin, cefepime, ceftaroline, ertapenem and oxacillin...The synergy demonstrated against these organisms supports the use of dalbavancin in combination with β-lactams against resistant phenotypes of S. aureus. Further evaluation is warranted.
  • ||||||||||  Orbactiv (oritavancin) / Melinta Therap, dalbavancin / RaQualia
    Journal:  Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays. (Pubmed Central) -  Jan 17, 2020   
    We observe very significant differences in measured MICs (up to 100-fold) for some lipophilic antibiotics, such as the Gram-positive lipoglycopeptide dalbavancin and the Gram-negative lipopeptide polymyxins, and find that non-specific binding plates can replace the need for surfactant additives. Microtitre plate types and any additives should be specified when reporting broth dilution MIC values as results can vary dramatically for some classes of antibiotics.
  • ||||||||||  dalbavancin / RaQualia
    Journal:  Can dalbavancin be used as a catheter lock solution? (Pubmed Central) -  Jan 10, 2020   
    Dalbavancin proved to be active against MRSA and MRSE biofilms. The combination of dalbavancin with heparin is a promising catheter lock solution that has the advantage of locking the catheter at home for 7 days.
  • ||||||||||  dalbavancin / RaQualia
    Journal:  Towards single-peak dalbavancin analogs through biology and chemistry. (Pubmed Central) -  Dec 20, 2019   
    The double mutant afforded the desired deacyl, deacetyl A40926 intermediates, which could be converted by chemical re-acylation yielding A40926 analogs with a greatly reduced number of congeners. The newly acylated analogs could then be transformed into dalbavancin analogs possessing the same in vitro properties as the approved drug.
  • ||||||||||  Zeven (dalbavancin) / RaQualia, AbbVie
    Enrollment open:  Xydalba Utilization Registry in Germany (clinicaltrials.gov) -  Dec 16, 2019   
    P=N/A,  N=150, Recruiting, 
    The newly acylated analogs could then be transformed into dalbavancin analogs possessing the same in vitro properties as the approved drug. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Novel developments in the treatment of acute bacterial skin and skin structure infections. (Pubmed Central) -  Oct 27, 2019   
    In theory, this may translate to reducing the utilization of healthcare resources by allowing for earlier discharge and reducing the need for outpatient parenteral therapy. While the approval of new agents offers the opportunity to improve and simplify treatment of ABSSSI, it is more important now than ever to use these agents in a responsible manner.
  • ||||||||||  dalbavancin / RaQualia
    Clinical, PK/PD data, Review, Journal:  Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. (Pubmed Central) -  Oct 9, 2019   
    Telavancin was discovered by modifying the chemical structure of vancomycin and belongs to the group of lipoglycopeptides...Although, in contrast to the newer lipoglycopeptides, telavancin demonstrates a relatively short half-life and rapid total clearance, its apparent volume of distribution (V) is almost identical to that of dalbavancin...Considering both the AUC24/MIC ratios of telavancin and the near complete equilibration of the free fraction in plasma with soft tissue, telavancin is an appropriate antimicrobial agent to treat soft tissue infections caused by Gram-positive pathogens. Although the penetration of telavancin into epithelial lining fluid (ELF) requires further investigations, the AUC24/MIC ratio for S. aureus indicates that bactericidal activity in the ELF could be expected.
  • ||||||||||  dalbavancin / RaQualia
    DOING MORE HARM THAN GOOD IN THE INTELLECTUALLY DELAYED PATIENTS (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_2692;    
    There are no easy decisions when it comes to management of end-of-life decisions in young adults. This case reinforced the need for interdisciplinary teams as well as reaching out to pediatric colleagues and other healthcare professionals for assistance when indicated.
  • ||||||||||  Journal:  Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. (Pubmed Central) -  Sep 19, 2019   
    They Include Ceftaroline (Teflaro), Dalbavancin (Dalvance), Oritavancin (orbativ), Tedizolid (Sevixtro), Delafloxacin (Baxdela) and Omadacycline (Nuzyra). This article will briefly review each of these new antibiotics and summarize their roles in avoiding hospital admissions and reducing the duration of stay in patients with SSTI.
  • ||||||||||  Oritavancin (LY333328) / The Medicines Company, dalbavancin / RaQualia
    Journal:  New developments in glycopeptide antibiotics. (Pubmed Central) -  Sep 14, 2019   
    The natural product monobactam, cephalosporin and beta-lactam antibiotics all spawned multiple generations of commercially and clinically successful semi-synthetic derivatives. Similarly, next-generation glycopeptides are now technically well positioned to advance to the clinic, if sufficient funding and market support returns to antibiotic development.
  • ||||||||||  vancomycin / generics
    Clinical, Review, Journal:  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin. (Pubmed Central) -  Sep 6, 2019   
    Use of higher vancomycin dosages in attempts to achieve higher trough concentrations has been associated with increased nephrotoxicity. New recently approved antibiotics including ceftaroline, dalbavancin, and tedizolid offer a number of advantages over vancomycin to treat staphylococcal infections: improved antimicrobial activity, superior pharmacokinetics, pharmacodynamics, tolerability, and dosing, including once-daily and weekly regimens, and less need for monitoring drug levels.
  • ||||||||||  Review, Journal:  Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. (Pubmed Central) -  Aug 22, 2019   
    As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.
  • ||||||||||  Oritavancin (LY333328) / The Medicines Company, dalbavancin / RaQualia
    Journal:  Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides. (Pubmed Central) -  Aug 7, 2019   
    Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.V. available standard therapy options.